Aquestive Therapeutics, Inc. AQST Personnel costs — R&D
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s personnel costs — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s personnel costs — R&D?
- Aquestive Therapeutics, Inc. (AQST) reported personnel costs — R&D of $2.24M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s personnel costs — R&D changed year-over-year?
- Aquestive Therapeutics, Inc.'s personnel costs — R&D increased by 5.2% year-over-year, from $2.13M to $2.24M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s personnel costs — R&D?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s personnel costs — R&D has grown at a 17.8% compound annual growth rate (CAGR), from $6.23M to $8.65M.
- What does personnel costs — R&D mean?
- This metric represents the total compensation and benefits expenses allocated to employees directly involved in research and development activities. It reflects the company's investment in human capital required to drive innovation, clinical trials, and the advancement of the product pipeline. Monitoring this cost helps investors assess the company's commitment to long-term growth through scientific development.